Trade

with

Quintiles Transnational Holdings Inc
(NYSE: Q)
AdChoices
57.56
+0.57
+1.00%
After Hours :
57.56
0.00
0.00%

Open

56.94

Previous Close

56.99

Volume (Avg)

591.94k (536.36k)

Day's Range

56.87-58.53

52Wk Range

40.10-58.89

Market Cap.

7.33B

Dividend Rate ( Yield )

-

Beta

-

Shares Outstanding

127.28M

P/E Ratio (EPS)

24.27 (2.37)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 5.10B

    • Net Income

    • 226.59M

    • Market Cap.

    • 7.33B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 6.03

    • PEG (Price/Earnings Growth) Ratio

    • 1.07

    • Beta

    • -

    • Forward P/E

    • 19.53

    • Price/Sales

    • 1.46

    • Price/Book Value

    • -11.79

    • Price/Cash flow

    • 17.57

      • EBITDA

      • 554.13M

      • Return on Capital %

      • 11.20

      • Return on Equity %

      • -

      • Return on Assets %

      • 11.20

      • Book Value/Share

      • -4.88

      • Shares Outstanding

      • 127.28M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 60.00

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • 2.62

        • Cashflow Estimate

        • 3.66

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 3.50

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • 27.60

          • -5.55

          • Net Income

            Q/Q (last year)

          • 121.00

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 27.12

            • 42.70

            • Pre-Tax Margin

            • 8.26

            • 11.63

            • Net Profit Margin

            • 6.03

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.62

              • Current Ratio

              • 1.38

              • 1.23

              • Quick Ratio

              • 1.27

              • 0.76

              • Interest Coverage

              • 5.10

              • 5.98

              • Leverage Ratio

              • -

              • 2.16

              • Book Value/Share

              • -4.88

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 24.27

                • 33.22

                • P/E Ratio 5-Year High

                • 24.82

                • 325.07

                • P/E Ratio 5-Year Low

                • 16.90

                • 154.73

                • Price/Sales Ratio

                • 1.46

                • 2.34

                • Price/Book Value

                • -11.79

                • 3.04

                • Price/Cash Flow Ratio

                • 17.57

                • 19.08

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • 11.20

                    (-)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • 10.26k

                  • 17.17k

                  • Inventory Turnover

                  • -

                  • 5.07

                  • Asset Turnover

                  • 1.86

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  462.33M
                  Operating Margin
                  9.07
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  17.57
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  100.80%

                  Mutual Fund Ownership

                  23.53%

                  Float

                  32.05%

                  5% / Insider Ownership

                  13.09%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Health Care Fund

                  •  

                    5,636,278

                  • 20.27

                  • 4.43

                  • Wells Fargo Advantage Growth Fund

                  •  

                    1,515,000

                  • -0.92

                  • 1.19

                  • Vanguard Mid-Cap Index Fund

                  •  

                    1,195,698

                  • 8.64

                  • 0.94

                  • Lord Abbett Fundamental Equity

                  •  

                    1,146,511

                  • 0.00

                  • 0.90

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,125,514

                  • 6.53

                  • 0.88

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    948,929

                  • 2.03

                  • 0.76

                  • Vanguard Strategic Equity Fund

                  •  

                    855,700

                  • 0.00

                  • 0.67

                  • Lord Abbett Value Opportunities Fund

                  •  

                    809,549

                  • -17.41

                  • 0.64

                  • Wells Fargo Advantage Prem Lg Co Gr

                  •  

                    774,797

                  • -13.75

                  • 0.61

                  • Franklin Small-Mid Cap Growth Fund

                  •  

                    728,400

                  • 0.00

                  • 0.57

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Bain Capital Investors LLC

                  •  

                    19,572,305

                  • 0.00%

                  • 15.40

                  • TPG Capital, L.P.

                  •  

                    14,036,629

                  • -18.98%

                  • 11.04

                  • 3i Investments PLC

                  •  

                    12,221,589

                  • 0.00%

                  • 9.61

                  • Wellington Management Company, LLP

                  •  

                    7,874,613

                  • +5.81%

                  • 6.19

                  • AllianceBernstein LP

                  •  

                    6,595,229

                  • +7.97%

                  • 5.19

                  • Temasek Holdings Ltd.

                  •  

                    6,383,856

                  • 0.00%

                  • 5.02

                  • Vanguard Group, Inc.

                  •  

                    4,718,169

                  • +15.15%

                  • 3.71

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Slow Growth

                  Style

                  Mid Core

                  Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcin...moreg services. The Company’s services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and func...moretional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as global laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides strategy and management consulting services based on life science expertise and advanced analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical devices, such as the FDA’s regulations against “off-label promotion,” which require sales representatives to restrict promotion of the approved product they are detailing to the approved labeling for the product, and the Prescription Drug Marketing Act which imposes licensing, personnel record keeping, packaging, labeling, product handling and facility storage and security requirements.lessless

                  Key People

                  Thomas Pike

                  CEO/Director

                  Dr. Dennis B. Gillings,PhD

                  Chairman of the Board/Director/Founder

                  Kevin K. Gordon

                  CFO/Executive VP

                  Dr. Derek M. Winstanly

                  Executive VP/Other Executive Officer

                  Mr. James H. Erlinger, III

                  Executive VP/General Counsel/Secretary

                  • Quintiles Transnational Holdings Inc

                  • 4820 Emperor Boulevard

                  • Durham, NC 27703

                  • USA.Map

                  • Phone: +1 919 998-2000

                  • Fax: -

                  • quintiles.com

                  Incorporated

                  1982

                  Employees

                  30,700

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: